Table 3.
Best Response in ALC and Nodes
| Best reduction ALC | N (%) | ||
|---|---|---|---|
| At least 10% decline | 28/42(67%) | ||
| At least 20% decline | 22/42(52%) | ||
| At least 30% decline | 12/42(29%) | ||
| At least 40% decline | 4/42(10%) | ||
| At least 50% decline | 3/42(7%) | ||
| Best reduction Lymphadenopathy | |||
| At least 50% reduction sum products | 20/29*(69%) | ||
| PR or Biologic Response | 29/42(69%) | ||
| PR or Biologic Response by Prognostic Parameter | Proportion with at Least Biologic Response | P value | |
| ZAP-70 | Negative(<20%) | 21/30(70%) | 1.0 |
| Positive(≥20%) | 8/12(67%) | ||
| CD38 | Negative(<30%) | 25/35(71%) | 0.66 |
| Positive(≥30%) | 4/7(57%) | ||
| IGHV | Mutated | 19/27(70%) | 1.0 |
| Unmutated | 5/6(83%) | ||
| FISH | (del)13q14.2 | 19/27(70%) | 0.84 |
| normal | 7 /10(70%) | ||
| Trisomy 12 | 2/4(50%) | ||
*
29 patients had palpable lymphadenopathy at study entry